KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.Clin Cancer ResPMID 37379430无 PMCID2023-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.JAMA OncolPMID 37440217PMC103465052023-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.JAMA OncolPMID 37471075PMC103600052023-Sep-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Zuranolone for the Treatment of Postpartum Depression.Am J PsychiatryPMID 37491938无 PMCID2023-Sep-010.98未发现恶性肿瘤人群证据。待处理
Lead Time to Recurrence After Posttreatment Plasma and Saliva HPV DNA Testing in Patients With Low-Risk HPV Oropharynx Cancer.JAMA Otolaryngol Head Neck SurgPMID 37498566PMC103753882023-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes Obes MetabPMID 37264711无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes Obes MetabPMID 37344954无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.Arthritis Care Res (Hoboken)PMID 36722450无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.Bipolar DisordPMID 36779257无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.J Thorac Cardiovasc SurgPMID 36841745无 PMCID2023-Sep0.90This is an exploratory analysis of safety and tolerability by surgery type from the randomized phase III IMpower010 trial. While the record is from a randomized, phase III, oncology, human, drug-intervention trial, the abstract focuses solely on adverse event rates and does not present a primary or key secondary time-to-event efficacy analysis.待处理
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.Pediatr ResPMID 36899125PMC100003532023-Sep0.98未发现恶性肿瘤人群证据。待处理
Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial.ChestPMID 37003355PMC118982242023-Sep0.98未发现恶性肿瘤人群证据。待处理
Vertebroplasty versus bracing in acute vertebral compression fractures: A prospective randomized trial.Ann Phys Rehabil MedPMID 37030247无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.J Gastrointest CancerPMID 37037952PMC106131412023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis.J RheumatolPMID 37061234无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.Arthritis RheumatolPMID 37098795无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Efficacy of imiquimod in the management of lentigo maligna.J Eur Acad Dermatol VenereolPMID 37114291无 PMCID2023-Sep0.85The trial is a phase III RCT in oncology (lentigo maligna) with a drug intervention, but it lacks a primary or key secondary time-to-event efficacy endpoint with reported time-to-event data (e.g., Kaplan-Meier, HR). The primary endpoint is surgical success, and secondary endpoints do not include reported time-to-event outcomes.待处理
Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial.J NeurotraumaPMID 37130044无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.Ophthalmol RetinaPMID 37179017无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).Lancet Infect DisPMID 37182534无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.J Am Acad DermatolPMID 37182701无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials.J Eur Acad Dermatol VenereolPMID 37184290无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial.Int J Infect DisPMID 37211270无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Vitamin D supplementation to prevent tuberculosis infection in South African schoolchildren: multicenter phase 3 double-blind randomized placebo-controlled trial (ViDiKids).Int J Infect DisPMID 37211272无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.Clin Pharmacol TherPMID 37212707无 PMCID2023-Sep0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).J Cancer Res Clin OncolPMID 37213030PMC103747762023-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).J Am Acad DermatolPMID 37230366无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.J Thorac OncolPMID 37236398无 PMCID2023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.J Eur Acad Dermatol VenereolPMID 37247226无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial.J NeurotraumaPMID 37279301PMC104606932023-Sep0.98未发现恶性肿瘤人群证据。待处理
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.Am J Clin DermatolPMID 37300760PMC104603742023-Sep0.98未发现恶性肿瘤人群证据。待处理
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.Lancet Infect DisPMID 37348519无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.Clin Colorectal CancerPMID 37355363无 PMCID2023-Sep0.85The report is a biomarker/prognostic subgroup analysis from a phase III randomized trial. While it is oncology, human, randomized, phase III, and reports time-to-event results, it does not explicitly establish a drug-containing intervention in the provided abstract. The analysis itself is secondary/subgroup, not the primary trial result.待处理
Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506).Breast Cancer Res TreatPMID 37365483PMC103618832023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.Ann OncolPMID 37399894PMC108494652023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.J InfectPMID 37406777无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Prostration and the prognosis of death in African children with severe malaria.Int J Infect DisPMID 37414210PMC76183912023-Sep0.98未发现恶性肿瘤人群证据。待处理
Aggressive local therapy for de novo metastatic breast cancer: Challenges and updates (Review).Oncol RepPMID 37449542PMC103947342023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Preoperative mechanical bowel preparation using conventional versus hyperosmolar polyethylene glycol-electrolyte lavage solution before laparoscopic resection for colorectal cancer (TLUMP test): a phase III, multicenter randomized controlled non-inferiority trial.J GastroenterolPMID 37462794无 PMCID2023-Sep0.93干预为非药物单独策略,未满足药物干预要求。待处理
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.Lancet HaematolPMID 37517413无 PMCID2023-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.Lancet HIVPMID 37567205无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.Lancet OncolPMID 37591293无 PMCID2023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.J Clin Hypertens (Greenwich)PMID 37614053PMC104970322023-Sep0.90The study is a Phase III randomized trial of a drug-containing triple combination therapy, but it is for hypertension (non-oncology) and its primary efficacy endpoint is a change in blood pressure, not a time-to-event outcome like OS, PFS, DFS, etc., or Kaplan-Meier/HR analysis.待处理
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.Nat MedPMID 37653342PMC105040662023-Sep0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.HeadachePMID 37655536无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.Lancet OncolPMID 37657460无 PMCID2023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.Target OncolPMID 37659025PMC105178842023-Sep0.95Meets all eligibility criteria: Phase 3 randomized trial in human oncology with a drug intervention and primary time-to-event efficacy endpoint.待处理
Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112.J Natl Compr Canc NetwPMID 37673107PMC105945402023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study.Clin Drug InvestigPMID 37682405PMC105141762023-Sep0.98未发现恶性肿瘤人群证据。待处理
Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer.JCO Clin Cancer InformPMID 37713655PMC105697752023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理